サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1498770

呼吸器系感染症治療市場：感染タイプ別、薬剤クラス別、投与経路別、エンドユーザー別、国別、地域別- 産業分析、市場規模、市場シェア、2024年～2032年の予測

Respiratory Tract Infection Treatment Market, By Infection Type, By Drug Class, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 269 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
呼吸器系感染症治療市場：感染タイプ別、薬剤クラス別、投与経路別、エンドユーザー別、国別、地域別- 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年06月04日
発行: AnalystView Market Insights
ページ情報: 英文 269 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

呼吸器系感染症治療市場規模は2023年に432億9,032万米ドルとなり、2024年から2032年にかけてCAGR 6.10％で拡大

呼吸器系感染症治療市場-市場力学

小児の呼吸器感染症有病率の高さが呼吸器系感染症治療市場のニーズを促進

小児における呼吸器感染症（RTI）の高い有病率が、呼吸器系感染症治療市場における効果的な治療法の必要性を大きく高めています。世界保健機関（WHO）によると、急性呼吸器感染症（ARI）は5歳未満の小児の主な死因であり、世界全体でこの年齢層の全死亡の約20％を占めています。米国疾病予防管理センター（CDC）の報告によると、毎年数百万人の子どもたちが肺炎や気管支炎などの呼吸器感染症に罹患しており、しばしば医療介入を必要としています。このような負担の増大は、高度な治療オプションの緊急な必要性を強調し、ヘルスケアプロバイダーや親がこれらの感染症と闘い、関連する健康合併症を減らすための効果的な解決策を求めているため、市場の需要を牽引しています。

呼吸器系感染症治療市場-主要インサイト

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2024-2032年）に約6.10%のCAGRで毎年成長すると推定されます。

感染タイプ別では、下気道感染症が2023年に最大市場シェアを占めると予測

薬剤クラス別では、2023年に抗生物質が主要タイプでした。

投与経路のセグメンテーションに基づくと、2023年には経口剤が主要タイプでした。

地域別では、北米が2023年に収益でリードしました。

呼吸器系感染症治療市場-セグメンテーション分析：

世界の呼吸器系感染症治療市場は、感染タイプ、薬剤クラス別、投与経路、エンドユーザー、地域に基づいてセグメント化されます。

市場は感染タイプに基づいて2つのカテゴリーに分けられる：上気道感染症」と「下気道感染症」です。上部呼吸器管感染症（URTI）セグメントは、風邪、副鼻腔炎、咽頭炎などの疾患の高い発生率に牽引され、市場を独占すると予想されます。一方、下気道感染症（LRTI）は、特に脆弱な人々の間で肺炎や気管支炎の有病率が上昇していることなどの要因により、大幅な成長が見込まれています。

市場は薬剤クラス別に5つのカテゴリーに分類される：抗生物質、抗ウイルス薬、抗真菌薬、副腎皮質ステロイド薬、気管支拡張薬です。抗生物質は、細菌による呼吸器感染症の治療に広く使用されていることから、市場シェアをリードすると予想されます。抗ウイルス薬は、特にインフルエンザなどのウイルス性呼吸器感染症の治療における進歩により、その後に続くと予測されます。一方、コルチコステロイド薬、抗真菌薬、気管支拡張薬は、特定の呼吸器疾患や患者のニーズに合わせて調整されるため、シェアは低くなると予想されます。

呼吸器系感染症治療市場-地理的洞察

呼吸器疾患の有病率の高さ、整備されたヘルスケアインフラ、研究開発活動の重視により、北米が市場シェアをリード。欧州は、ヘルスケア支出の増加、有利な償還政策、呼吸器疾患に罹患しやすい高齢者人口の増加を背景に、これに続いています。アジア太平洋地域は、急速な都市化、汚染レベルの上昇、呼吸器の健康に対する意識の高まりに後押しされ、大きな成長を遂げようとしています。同地域の人口の多さと中間層の拡大も、呼吸器系感染症治療の需要拡大に寄与しています。ラテンアメリカや中東・アフリカ地域の新興経済圏も、ヘルスケアアクセスの改善、可処分所得の増加、ヘルスケアインフラ強化のための政府の取り組みに後押しされ、著しい成長を遂げています。市場プレーヤーは、未開拓の機会を活用し、強固な足場を築くために、戦略的にこれらの地域に焦点を当てています。

呼吸器系感染症治療市場-競合情勢：

市場の主要プレーヤーには、グラクソ・スミスクライン、ノバルティス、ファイザー、アストラゼネカ、サノフィなどの製薬企業が含まれます。これらの企業は、市場での存在感を高めるため、革新的な治療法の開発、製品ポートフォリオの拡充、販売網の強化に注力しています。市場開拓企業はまた、新規治療薬の導入や既存治療法の改良のための研究開発にも多額の投資を行い、医療従事者や患者のニーズの変化に対応しています。さらに、専門知識、リソース、規制上の支援を活用するため、ヘルスケア機関、学術機関、政府機関との戦略的提携を結ぶケースも増えています。効果的な呼吸器系感染症治療に対する需要が世界的に高まる中、市場競争は激化し、この分野での技術革新や進歩が進むと予想されます。

目次

第1章 呼吸器系感染症治療市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 呼吸器系感染症治療の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 呼吸器系感染症治療産業の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 呼吸器系感染症治療市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 呼吸器系感染症治療市場情勢

  • 呼吸器系感染症治療市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 呼吸器系感染症治療市場：感染症タイプ別

  • 概要
    • 感染症タイプ別セグメントシェア分析
    • 上気道感染症（URTI）
    • 下気道感染症（LRTI）

第8章 呼吸器系感染症治療市場：薬剤クラス別

  • 概要
    • 薬剤クラス別セグメントシェア分析
    • 抗生物質
    • 抗ウイルス薬
    • 抗真菌薬
    • コルチコステロイド
    • 気管支拡張薬
    • その他

第9章 呼吸器系感染症治療市場：投与経路別

  • 概要
    • 投与経路別セグメントシェア分析
    • 経口
    • 注射
    • 吸入
    • 外用

第10章 呼吸器系感染症治療市場：エンドユーザー別

  • 概要
    • エンドユーザー別セグメントシェア分析
    • 病院
    • クリニック
    • 外来手術センター
    • ホームケア設定

第11章 呼吸器系感染症治療市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析：呼吸器系感染症治療業界

  • 競合ダッシュボード
  • 企業プロファイル
    • AbbVie Inc.
    • AstraZeneca plc
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Cipla Limited
    • F. Hoffmann-La Roche AG
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Johnson &Johnson
    • Merck &Co., Inc.
    • Mylan NV（now part of Viatris Inc.）
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Others

第13章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Respiratory Tract Infection Treatment Market: Infection Type Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Infection Type
  • TABLE Global Respiratory Tract Infection Treatment Market, by Infection Type 2019-2032 (USD Million)
  • TABLE Respiratory Tract Infection Treatment Market: Drug Class Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Respiratory Tract Infection Treatment Market, by Drug Class 2019-2032 (USD Million)
  • TABLE Respiratory Tract Infection Treatment Market: Route of Administration Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Route of Administration
  • TABLE Global Respiratory Tract Infection Treatment Market, by Route of Administration 2019-2032 (USD Million)
  • TABLE Respiratory Tract Infection Treatment Market: End-User Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by End-User
  • TABLE Global Respiratory Tract Infection Treatment Market, by End-User 2019-2032 (USD Million)
  • TABLE Respiratory Tract Infection Treatment Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Respiratory Tract Infection Treatment Market, by Region 2019-2032 (USD Million)
  • TABLE North America Respiratory Tract Infection Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Respiratory Tract Infection Treatment Market, by Infection Type, 2019-2032 (USD Million)
  • TABLE North America Respiratory Tract Infection Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE North America Respiratory Tract Infection Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • TABLE North America Respiratory Tract Infection Treatment Market, by End-User, 2019-2032 (USD Million)
  • TABLE Europe Respiratory Tract Infection Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Respiratory Tract Infection Treatment Market, by Infection Type, 2019-2032 (USD Million)
  • TABLE Europe Respiratory Tract Infection Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Europe Respiratory Tract Infection Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • TABLE Europe Respiratory Tract Infection Treatment Market, by End-User, 2019-2032 (USD Million)
  • TABLE Asia Pacific Respiratory Tract Infection Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Respiratory Tract Infection Treatment Market, by Infection Type, 2019-2032 (USD Million)
  • TABLE Asia Pacific Respiratory Tract Infection Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Asia Pacific Respiratory Tract Infection Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • TABLE Asia Pacific Respiratory Tract Infection Treatment Market, by End-User, 2019-2032 (USD Million)
  • TABLE Latin America Respiratory Tract Infection Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Respiratory Tract Infection Treatment Market, by Infection Type, 2019-2032 (USD Million)
  • TABLE Latin America Respiratory Tract Infection Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Latin America Respiratory Tract Infection Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • TABLE Latin America Respiratory Tract Infection Treatment Market, by End-User, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Respiratory Tract Infection Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Respiratory Tract Infection Treatment Market, by Infection Type, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Respiratory Tract Infection Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Respiratory Tract Infection Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Respiratory Tract Infection Treatment Market, by End-User, 2019-2032 (USD Million)
目次
Product Code: ANV2941

REPORT HIGHLIGHT

Respiratory Tract Infection Treatment Market size was valued at USD 43,290.32 Million in 2023, expanding at a CAGR of 6.10% from 2024 to 2032.

The Respiratory Tract Infection Treatment Market, encompassing therapies and medications for ailments affecting the respiratory system, is poised for significant growth driven by the rising prevalence of respiratory diseases, increasing air pollution, and the growing geriatric population. Key driving factors include advancements in diagnostic technologies, increased healthcare expenditure, and heightened awareness of respiratory health. However, the market faces restraints such as stringent regulatory frameworks and potential side effects of treatments. Opportunities abound in the form of emerging markets, innovative drug development, and increasing adoption of telemedicine and personalized medicine, which are expected to enhance treatment efficacy and accessibility.

Respiratory Tract Infection Treatment Market- Market Dynamics

High Prevalence of Respiratory Tract Infections Among Children Fuels Need of the Respiratory Tract Infection Treatment Market

The high prevalence of respiratory tract infections (RTIs) among children is significantly fueling the need for effective treatments in the Respiratory Tract Infection Treatment Market. According to the World Health Organization (WHO), acute respiratory infections (ARIs) are a leading cause of death in children under five years old, accounting for approximately 20% of all deaths in this age group globally. The Centers for Disease Control and Prevention (CDC) report that millions of children are affected by respiratory infections such as pneumonia and bronchitis each year, often requiring medical intervention. This growing burden underscores the urgent need for advanced treatment options, driving demand in the market as healthcare providers and parents seek effective solutions to combat these infections and reduce associated health complications.

Respiratory Tract Infection Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.10% over the forecast period (2024-2032)

Based on Infection Type segmentation, Lower Respiratory Tract Infections was predicted to show maximum market share in the year 2023

Based on Drug Class segmentation, Antibiotics was the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Respiratory Tract Infection Treatment Market- Segmentation Analysis:

The Global Respiratory Tract Infection Treatment Market is segmented on the basis of Infection Type, Drug Class, Route of Administration, End-User, and Region.

The market is divided into two categories based on Infection Type: Upper Respiratory Tract Infections, and Lower Respiratory Tract Infections. The upper Respiratory Tract Infections (URTI) segment is anticipated to dominate the market, driven by the high incidence of conditions such as common cold, sinusitis, and pharyngitis. Meanwhile, Lower Respiratory Tract Infections (LRTI) are expected to witness substantial growth due to factors including the rising prevalence of pneumonia and bronchitis, particularly among vulnerable populations.

The market is divided into five categories based on Drug Class: Antibiotics, Antiviral Drugs, Antifungal Drugs, Corticosteroids, and Bronchodilators. Antibiotics are expected to lead in market share, driven by their widespread use in treating respiratory infections caused by bacteria. Antiviral drugs are projected to follow, especially with advancements in treating viral respiratory infections like influenza. Meanwhile, corticosteroids, antifungal drugs, and bronchodilators are anticipated to have lower shares, tailored to specific respiratory conditions and patient needs.

Respiratory Tract Infection Treatment Market- Geographical Insights

North America leading in market share due to the high prevalence of respiratory diseases, well-established healthcare infrastructure, and strong emphasis on research and development activities. Europe follows suit, driven by increasing healthcare expenditure, favorable reimbursement policies, and a growing geriatric population prone to respiratory ailments. The Asia Pacific region is poised for significant growth, fueled by rapid urbanization, rising pollution levels, and increasing awareness of respiratory health. The region's large population base and expanding middle class also contribute to greater demand for respiratory tract infection treatments. Emerging economies in Latin America and the Middle East & Africa regions are also witnessing notable growth, propelled by improving healthcare access, rising disposable incomes, and government initiatives to enhance healthcare infrastructure. Market players strategically focus on these regions to capitalize on untapped opportunities and establish a strong foothold.

Respiratory Tract Infection Treatment Market- Competitive Landscape:

Major players in the market include pharmaceutical companies such as GlaxoSmithKline plc, Novartis AG, Pfizer Inc., AstraZeneca plc, and Sanofi S.A. These companies focus on developing innovative treatments, expanding their product portfolios, and strengthening their distribution networks to enhance market presence. Market players also invest significantly in research and development to introduce novel therapeutics and improve existing treatment options, catering to the evolving needs of healthcare providers and patients. Moreover, strategic alliances with healthcare organizations, academic institutions, and government bodies are increasingly being forged to leverage expertise, resources, and regulatory support. With the growing demand for effective respiratory tract infection treatments worldwide, competition among market players is expected to intensify, leading to ongoing innovations and advancements in the field.

Recent Developments:

In July 2023, the FDA approved Beyfortus (nirsevimab-alip) jointly developed by Sanofi and AstraZeneca. It's a monoclonal antibody designed to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants and children under 24 months with a single intramuscular injection.

In May 2023, the FDA approved Arexvy, the inaugural RSV vaccine by GlaxoSmithKline Biologicals, for use in the United States. Arexvy is specifically indicated to prevent respiratory syncytial virus (RSV) and lower respiratory tract disease in individuals aged 60 and above.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RESPIRATORY TRACT INFECTION TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AbbVie Inc.

AstraZeneca plc

Bayer AG

Boehringer Ingelheim International GmbH

Cipla Limited

F. Hoffmann-La Roche AG

Gilead Sciences, Inc.

GlaxoSmithKline plc

Johnson & Johnson

Merck & Co., Inc.

Mylan N.V. (now part of Viatris Inc.)

Novartis AG

Pfizer Inc.

Sanofi S.A.

Sun Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.

Others

GLOBAL RESPIRATORY TRACT INFECTION TREATMENT MARKET, BY INFECTION TYPE- MARKET ANALYSIS, 2019 - 2032

  • Upper Respiratory Tract Infections (URTI)
  • Lower Respiratory Tract Infections (LRTI)

GLOBAL RESPIRATORY TRACT INFECTION TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Antibiotics
  • Antiviral Drugs
  • Antifungal Drugs
  • Corticosteroids
  • Bronchodilators
  • Others

GLOBAL RESPIRATORY TRACT INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable
  • Inhalation
  • Topical

GLOBAL RESPIRATORY TRACT INFECTION TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Homecare Settings

GLOBAL RESPIRATORY TRACT INFECTION TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Respiratory Tract Infection Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Respiratory Tract Infection Treatment Market Snippet by Infection Type
    • 2.1.2. Respiratory Tract Infection Treatment Market Snippet by Drug Class
    • 2.1.3. Respiratory Tract Infection Treatment Market Snippet by Route of Administration
    • 2.1.4. Respiratory Tract Infection Treatment Market Snippet by End-User
    • 2.1.5. Respiratory Tract Infection Treatment Market Snippet by Country
    • 2.1.6. Respiratory Tract Infection Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Respiratory Tract Infection Treatment Key Market Trends

  • 3.1. Respiratory Tract Infection Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Respiratory Tract Infection Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Respiratory Tract Infection Treatment Market Opportunities
  • 3.4. Respiratory Tract Infection Treatment Market Future Trends

4. Respiratory Tract Infection Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Respiratory Tract Infection Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Respiratory Tract Infection Treatment Market Landscape

  • 6.1. Respiratory Tract Infection Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Respiratory Tract Infection Treatment Market - By Infection Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Infection Type, 2023 & 2032 (%)
    • 7.1.2. Upper Respiratory Tract Infections (URTI)
    • 7.1.3. Lower Respiratory Tract Infections (LRTI)

8. Respiratory Tract Infection Treatment Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 8.1.2. Antibiotics
    • 8.1.3. Antiviral Drugs
    • 8.1.4. Antifungal Drugs
    • 8.1.5. Corticosteroids
    • 8.1.6. Bronchodilators
    • 8.1.7. Others

9. Respiratory Tract Infection Treatment Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Injectable
    • 9.1.4. Inhalation
    • 9.1.5. Topical

10. Respiratory Tract Infection Treatment Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Clinics
    • 10.1.4. Ambulatory Surgical Centers
    • 10.1.5. Homecare Settings

11. Respiratory Tract Infection Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Respiratory Tract Infection Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Respiratory Tract Infection Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Respiratory Tract Infection Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Respiratory Tract Infection Treatment Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Respiratory Tract Infection Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Respiratory Tract Infection Treatment Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. AbbVie Inc.
    • 12.2.2. AstraZeneca plc
    • 12.2.3. Bayer AG
    • 12.2.4. Boehringer Ingelheim International GmbH
    • 12.2.5. Cipla Limited
    • 12.2.6. F. Hoffmann-La Roche AG
    • 12.2.7. Gilead Sciences, Inc.
    • 12.2.8. GlaxoSmithKline plc
    • 12.2.9. Johnson & Johnson
    • 12.2.10. Merck & Co., Inc.
    • 12.2.11. Mylan N.V. (now part of Viatris Inc.)
    • 12.2.12. Novartis AG
    • 12.2.13. Pfizer Inc.
    • 12.2.14. Sanofi S.A.
    • 12.2.15. Sun Pharmaceutical Industries Ltd.
    • 12.2.16. Teva Pharmaceutical Industries Ltd.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us